Mutant fragments of ospa and methods and uses relating thereto
US-2017101446-A1 · Apr 13, 2017 · US
Mutant fragments of OspA and methods and uses relating thereto
US9975927B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9975927-B2 |
| Application number | US-201515110151-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 9, 2015 |
| Priority date | Jan 9, 2014 |
| Publication date | May 22, 2018 |
| Grant date | May 22, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to compositions and methods for the prevention and treatment of Borrelia infection. Particularly, the present invention relates to a polypeptide comprising a hybrid C-terminal fragment of an outer surface protein A (OspA), a nucleic acid coding the same, an antibody specifically binding the same, a pharmaceutical composition (particularly for use as a medicament or in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid and/or the antibody, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.
First claim
Opening claim text (preview).
The invention claimed is: 1. A polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO: 27. 2. A pharmaceutical composition comprising the polypeptide according to claim 1 , and optionally a pharmaceutically acceptable carrier or excipient. 3. The pharmaceutical composition according to claim 2 , wherein the pharmaceutically acceptable excipient comprises L-methionine and/or aluminium hydroxide. 4. A pharmaceutical composition comprising the amino acid sequences of SEQ ID NO: 29, SEQ ID NO: 27 and SEQ ID NO: 33. 5. The polypeptide according to claim 1 for use in a method of treating or protecting against a Borrelia infection, wherein the Borrelia infection is a B. burgdorferi s.s. or B. afzelii infection. 6. The pharmaceutical composition according to claim 2 for use in a method of treating or protecting against a Borrelia infection, wherein the Borrelia infection is a B. burgdorferi s.s. or B. afzelii infection. 7. The pharmaceutical composition according to claim 4 , wherein the pharmaceutical composition is a vaccine. 8. The pharmaceutical composition according to claim 4 , further comprising a pharmaceutically acceptable carrier or excipient. 9. The pharmaceutical composition according to claim 8 , wherein the pharmaceutically acceptable excipient comprises L-methionine and/or aluminium hydroxide. 10. The pharmaceutical composition according to claim 2 , wherein the pharmaceutical composition is a vaccine. 11. The pharmaceutical composition according to claim 4 for use in a method of treating or protecting against a Borrelia infection, wherein the Borrelia infection is B. burgdorferi s.s. or B. afzelii infection.
Assignees
Inventors
Classifications
Antibacterial agents · CPC title
Antivirals · CPC title
Fusion polypeptide · CPC title
containing a His-tag · CPC title
Multivalent vaccine · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9975927B2 cover?
- The present invention relates to compositions and methods for the prevention and treatment of Borrelia infection. Particularly, the present invention relates to a polypeptide comprising a hybrid C-terminal fragment of an outer surface protein A (OspA), a nucleic acid coding the same, an antibody specifically binding the same, a pharmaceutical composition (particularly for use as a medicament …
- Who is the assignee on this patent?
- Valneva Austria Gmbh
- What technology area does this patent fall under?
- Primary CPC classification C07K14/20. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue May 22 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).